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ABSTRACT
Duchenne muscular dystrophy (DMD) is a genetic
neuromuscular disorder caused by the absence of
dystrophin. We developed a novel gene therapy ap-
proach based on the use of the piggyBac (PB) trans-
poson system to deliver the coding DNA sequence
(CDS) of either full-length human dystrophin (DYS:
11.1 kb) or truncated microdystrophins (MD1: 3.6
kb; MD2: 4 kb). PB transposons encoding microdys-
trophins were transfected in C2C12 myoblasts, yield-
ing 65±2% MD1 and 66±2% MD2 expression in dif-
ferentiated multinucleated myotubes. A hyperactive
PB (hyPB) transposase was then deployed to en-
able transposition of the large-size PB transposon
(17 kb) encoding the full-length DYS and green flu-
orescence protein (GFP). Stable GFP expression
attaining 78±3% could be achieved in the C2C12
myoblasts that had undergone transposition. West-
ern blot analysis demonstrated expression of the
full-length human DYS protein in myotubes. Subse-
quently, dystrophic mesoangioblasts from a Golden
Retriever muscular dystrophy dog were transfected
with the large-size PB transposon resulting in 50±5%
GFP-expressing cells after stable transposition. This
was consistent with correction of the differentiated
dystrophic mesoangioblasts following expression of
full-length human DYS. These results pave the way
toward a novel non-viral gene therapy approach for
DMD using PB transposons underscoring their po-
tential to deliver large therapeutic genes.
INTRODUCTION
Duchennemuscular dystrophy (DMD) is amongst the most
severe forms of muscular dystrophies, affecting up to 1 in
5000 boys (1). DMD is an X-linked disorder caused by
mutations or deletions in the gene encoding dystrophin
(2), which is required for the assembly of the dystrophin-
glycoprotein complex (3,4). This complex is responsible of
maintaining the integrity of the sarcolemma during muscle
contraction, providing amechanical and functional link be-
tween the cytoskeleton of the muscle fiber and the extracel-
lular matrix. The absence of dystrophin causes DMD, a se-
vere inheritable myopathy with its onset in the first years of
life. This pathology leads to a progressive muscle weakness,
consistent with fiber degeneration, inflammation, necrosis
and replacement of muscle with scar and fat tissue (5). Im-
pairment of the patient’s daily functional abilities rapidly re-
sults in a profound reduction in quality of life together with
a shortened life expectancy,mainly due to cardiac and respi-
ratory failure. The current standard of care involves the use
of anti-inflammatory and immunosuppressive drugs (e.g.
corticosteroids), that have shown to modestly improve mus-
cle function (6–9), prolonging the patient’s life expectancy
up to 30 years of age. Nevertheless, it is necessary to develop
*To whom correspondence should be addressed. Tel: +32 477529653; Fax: +32 24774159; Email: marinee.chuah@vub.ac.be
†These authors share joint senior authorship.
C© The Author(s) 2015. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/), which
permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
 Nucleic Acids Research Advance Access published December 17, 2015
 at R
oyal H
ollow
ay U
niversity of London on D
ecem
ber 23, 2015
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
2 Nucleic Acids Research, 2015
effective therapies that also counteract muscle degeneration
in DMD patients and have a more profound impact of the
patient’s quality of life and life expectancy.
Several approaches are currently being pursued to
address this unmet medical need, aimed at restoring
dystrophin expression (10,11). Exon-skipping approaches
based on antisense oligonucleotides had been proposed as a
promising strategy to correct the reading frame and restore
dystrophin expression (12,13). However, exon skipping is
only applicable to a subset of patients with specific muta-
tions and ultimately leads to the production of a truncated
dystrophin protein, similar to that found in patients affected
by Becker muscular dystrophy (BMD). This is a milder al-
lelic form of muscular dystrophy, that can still cause signif-
icant disability (14,15). Consequently, exon-skipping does
not replicate and fully reconstitute all of the essential func-
tions of dystrophin (16,17). Although encouraging, exon
skipping therapies are only recently entering clinical exper-
imentation in larger patient cohorts, with unclear efficacy
results in some cases (18).
Gene therapy for DMD is particularly challenging given
the large size of the dystrophin gene (2.4 Mb) and its cor-
responding CDS (11.1 kb) (19,20). Moreover, in vivo gene
therapy using viral vectors like helper-dependent adenovi-
ral vectors are able to provide the full-length dystrophin
CDS, but show limitations related to the delivery of a thera-
peutic dose to the entire body musculature (21,22). Adeno-
associated viral (AAV) vectors might be considered as a
good alternative for an efficient systemic delivery in the
muscles, but their use is impeded by their restricted packag-
ing capacity (23–26). This precludes gene therapy with the
full-length human dystrophin CDS and requires truncated
human dystrophin isoforms instead. Moreover, the use of
viral vectors may evoke potential immune responses against
the vector and/or the gene-modified cells (27–30). Hence,
there is a need to develop strategies that allow for efficient
and safe delivery of the full-length dystrophin CDS.
In the current study, we therefore validated a new gene
therapy approach that aims to overcome some of these lim-
itations, allowing stable gene delivery of the full-length hu-
man dystrophin CDS. To achieve this goal, we explored the
use of a hyperactive piggyBac (PB) transposon system, that
reportedly can accommodate relatively large inserts (31–
33). PB transposons, originally identified in the cabbage
looper moth Trichoplusia ni (34,35), have been adapted for
use in mammalian cells, following codon-usage optimiza-
tion and incorporation of several hyper-activating muta-
tions (33,36–38). For gene therapy, an expression plasmid
that encodes for the PB transposase is transiently trans-
fected along with a donor plasmid containing the thera-
peutic gene, flanked by the transposon terminal repeat se-
quences (39). The binding of the PB transposase in the ter-
minal repeat sequences enables transposition via a cut-and-
paste mechanism (40). To develop a PB transposon-based
stem cell/gene therapy approach for DMD, we chose to em-
ploy mesoangioblasts (MABs) (41–43). MABs are meso-
dermal vessel-associated stem/progenitor cells that have the
capacity to cross the vessel wall upon intra-arterial trans-
plantation and contribute to the regeneration of dystrophic
muscles (44–48). This occurs either by direct fusion with
the muscle or by entering the muscle satellite cell niche
(43,47). The therapeutic potential of MABs has been inves-
tigated in a recently completed phase I/II clinical trial based
on the intra-arterial transplantation of allogeneic cells in
five DMD patients under immunosuppressive regimen (Eu-
draCTN◦ 2011–000176–33) (49). The outcome of this study
provides new insights primarily on the safety and partially
on the efficacy of the use of MABs to treat DMD patients.
Moreover, this approach differed from other clinical trials
based on the intravenous administration of cells that get
trapped in the filter organs (50,51). Thus it represents the
starting point for the development of efficient cell therapy
protocols for DMD based on the use of gene-modified au-
tologous MABs with the advantage over allogeneic MABs
to possibly avoid the immune suppression.
Therefore, in the current study, we provided - for the first
time - proof of concept that the hyperactivePB transposons
are well suited to genetically correct dystrophic MABs, by
delivering the full-length human dystrophin CDS.
MATERIALS AND METHODS
Cell cultures
C2C12 myoblasts ((91031101; Sigma-Aldrich; (52)) were
cultured, as previously described (53), in D20medium com-
posed of high glucose Dulbecco’s modified Eagle’s medium
(DMEM; Life Technologies) supplemented with 20% Fe-
tal Bovine Serum (FBS; Life Technologies), 2 mM L-
glutamine (Life Technologies), 100 IU/ml penicillin and
100 g/ml streptomycin (P/S; Life Technologies), at 37◦C
in a 5%CO2 cell culture incubator. A biopsy from aGolden
Retriever muscular dystrophy (GRMD) dog was kindly
provided by Dr Richard from Le Centre de Boisbonne-
ONIRIS (Nantes-Atlantique, France). Canine mesoan-
gioblasts (MABs) were isolated and maintained in culture,
as described previously (45,53). Briefly, a biopsy from the
vastus lateralis muscle of a 10-month-old male dog was
minced in 1mm2 pieces. These fragments were transferred
onto collagen type I-coated dishes (Sigma-Aldrich) and in-
cubated in growth medium composed ofMegaCell DMEM
(Sigma-Aldrich) containing 5% FBS (Life Technologies),
0.1 mM -mercaptoethanol (Life Technologies), 1%MEM
non-essential amino acids (Life Technologies), 1% P/S, 1%
L-glutamine, 5 ng/ml human basic fibroblast growth fac-
tor (Peprotech) at 37◦C in a 5% CO2, 3% O2 cell culture
incubator. After 5 to 7 days, small, round, refractile cells
(Supplementary Figure S1A) that adheredweakly to the ini-
tial cell outgrowth were identified. This cell population was
collected and maintained in growth medium on collagen-
coated flasks. In order to confirm that the identified pop-
ulation was composed of bona fide MABs, cells were char-
acterized for the typical markers of adult dog MABs, after
five and ten passages (Supplementary Figure S1B–E). The
alkaline phosphatase expression was detected by enzymatic
activity using the NBT/BCIP kit (Roche). The staining was
performed on fixed cells in order to allow the formation of a
black/purple precipitate in the cells expressing the enzyme
(Supplementary Figure S1B). Moreover, their capacity to
differentiate into mesodermal lineages was analyzed by as-
sessing their intrinsic differentiation potential into multin-
ucleated skeletal myotubes or, under appropriated stimuli,
into smooth muscle cells (Supplementary Figure S1F, SG;
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see specific section ‘In vitro differentiation assay’). Human
skeletal muscle cells (SKM; C-12530; Promocell) were used
as positive control and cultured in the same condition of
GRMDMABs.
Transposase and transposon constructs
The piggyBac (PB) transposase constructs encoding the
native PB transposase (mPB) or the hyperactive PB
transposase (hyPB) were described previously (54). An
identical expression plasmid devoid of the PB trans-
posase gene (denoted as empty) was used as control
(Figure 1). The PB transposon constructs were gen-
erated after synthesis of the wild type sequences of
the PB terminal inverted repeats (IRs; Gene Synthesis,
Canada) and cloning into the pBluescript II SK (+)
plasmid upon digestion with BssHII restriction enzyme
(55,56). To produce the transposons PB-SPc-MD1 and
PB-SPc-MD2, the muscle-specific synthetic promoter
SPc5–12 (57) was amplified with primers (forward: 5′-
ATAGCTAGCCAGATCGAGCTCCACCGCGGT-3′;
reverse: 5′-ATAACGCGTGAATTCCTGCAGCCCGG
GGG-3′) adding flanking NheI and MluI restriction
sites, and ligated between the 5′ and 3′ IRs. This inter-
mediate plasmid, designated as PB-SPc5–12, was used
to insert the codon-usage optimized CDS of human
microdystrophin MD1 or MD2 (58,59), together with
the simian virus 40 (SV40) late polyadenylation (pA)
signal, after amplification with primers (forward: 5′-
ATAACGCGTGCCACCATGCTGTGGTGGGAG-3′;
reverse: 5′-ATACTCGAGGTTTATTGCAGCTTATA
ATGGTTACAAATAAAGCAATAGCATCA-3′) and
digestion withMluI and XhoI restriction enzymes. To gen-
erate the transposon PB-SPc-GFP, the SV40 pA sequence
was amplified with primers (forward: 5′-ATAACGCG
TCAGACATGATAAGATACATTGATG-3′; reverse: 5′-
ATACTCGAGGTTTATTGCAGCTTATAATGGTT-3′)
adding flankingMluI and XhoI restriction sites, and ligated
into the intermediate plasmid PB-SPc5–12. Then the trans-
gene copepod GFP (Lonza) was PCR-amplified (forward:
5′-ATAACTAGTAGCGCTACCGGTCGCCACC-3′;
reverse: 5′-ATAACGCGTAGATCTGGCGAAGGC
GATGGG-3′) flanked by SpeI and MluI restriction
sites and cloned between the SPc5–12 promoter and
the SV40 pA signal. To produce the transposon PB-
Pgk-GFP, the PCR primers (forward: 5′-GTACGGCT
AGCGTTAACAATTCTACCGGGTAGG-3′, reverse:
5′-GACGTAGCGCTATGCAGGTCGAAAGGC-3′)
containing NheI and Eco47III restriction sites were used
to amplify the Pgk promoter (Addgene) and cloned it into
the correspondent sites of PB-SPc5–12 in order to replace
SPc5–12 promoter. For the construction of the large size
transposon PB-SPc-DYS-Pgk-GFP, the following frag-
ment SPc5–12 promoter-KpnI-NheI-SgsI-SV40 pA signal
has been synthesized (DNA cloning, Germany) adding
flanking restriction sites NotI and XhoI, and inserted
between the 5′ and 3′ PB IRs of the pBluescript II SK
(+) plasmid. This allowed the ligation of the codon usage
optimized full-length human dystrophin CDS (Jarmin
et al., unpublished) upon digestion first with KpnI and
NheI, and then with NheI and SgsI restriction enzymes.
The GFP reporter gene was then inserted together with
the Pgk promoter and the SV40 pA signal downstream
the full-length human dystrophin expression cassette using
HpaI and XhoI restriction sites. The entire expression
cassette of all the PB transposons was flanked with loxP
sites allowing for a possible subsequent excision by CRE
recombinase (39,60). The sequences of the constructs
involving PCR-based cloning were confirmed by DNA
sequencing.
Transfection
Cells were electroporated with the Amaxa Nucleofector II
(Lonza). For C2C12 myoblasts, the Cell Line Nucleofector
Kit V and the program B-32 were used. Whilst for GRMD
MABs, the Human MSC Nucleofector Kit and the pro-
gram U-23 were applied. Transfections were optimized to
obtain good efficiency with low levels of toxicity, modifying
the amount of plasmids used and the transposase: trans-
poson ratio. Briefly, cells were trypsinized, washed in PBS
(Life Technologies) and counted; 1×106 cells were electro-
porated and subsequently seeded in a single dish of a 6-well
multidish (Nunc). The day after, the medium was replaced
with fresh medium. Transfection efficiency was assessed by
calculating the percentage of GFP+ cells at 24, 48 and
72 h post-electroporation (EP) by fluorescence microscopy
and/or fluorescence activated cells sorter (FACSCantoTM
flow cytometer, Becton Dickinson). In this case, transfected
C2C12 cells or GRMD MABs were therefore trypsinized,
washed in PBS, counted and resuspended into PBS supple-
mented with 1% FBS and 2mMEDTA (Life Technologies).
Analyses were performed with FACSDiva software. Where
indicated,GFP positive C2C12 cells orGRMDMABswere
enriched respectively at day 4 and 7 days post-EP by FACS
sorting (BD FACSAria, Becton Dickinson). Transfected
cells weremonitored for 28–30 days post-EP to assess trans-
position efficiency.
Transduction
GRMD MABs were transduced with a lentiviral vec-
tor containing a tamoxifen-inducible MyoD-ER expres-
sion cassette (61) to induce myogenic differentiation at
late passages (i.e. passage P15–18). Lentiviral vector titra-
tion was calculated based upon the p24 assay (QuickTiter
Lentivirus Quantitation Kit, Cellbiolabs). Working con-
centrations were determined by assessing myogenic differ-
entiation efficiency at increasing multiplicities of infection
(MOI). Briefly, 0.14 × 106 cells were transduced with 1, 5
or 50 MOI of MyoD-ER lentiviral vector in 1 ml of culture
medium and incubated for 12 h at 37◦C in a 5% CO2, 3%
O2 cell culture incubator.Mediawere subsequently changed
and cells maintained in culture for 2–3 passages, after which
the in vitro differentiation assay into skeletalmuscle was per-
formed (see specific section below). The optimal condition
was set at 50 MOI.
In vitro differentiation assays
The ability of C2C12 cells, GRMD MABs and SKM cells
to differentiate into skeletal muscle was assessed in vitro by
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Figure 1. Schematic representation of PB transposon and PB transposase constructs. (A) PB-SPc-DYS-Pgk-GFP transposon encoding the codon opti-
mized full-length human dystrophin CDS (huDYSco; (59)) is represented as in its four major structural domains: N-terminal domain (N), a central rod
domain, a cysteine-rich (CR) domain and a distal C-terminal domain (C). The central rod domain contains 24 triple-helix rod repeats and four hinges
(H1–H4). The full-length human dystrophin CDS is driven by the muscle-specific synthetic promoter SPc5–12 (57). Downstream, the sequence of a cope-
pod GFP has been cloned as a reporter driven by the Pgk promoter. (B,C) PB-SPc-MD1 and PB-SPc-MD2 transposons encode respectively for huMD1co
and huMD2co CDS; these are two different codon optimized human microdystrophins that lack the original sequence of rod repeats 4–23 and differ for
the presence of the C-terminal domain sequence inMD2 (59). This extra sequence has been shown to improve the efficiency on restoring muscle function
in dystrophic mdx mice (58). Both the microdystrophins are driven by SPc5–12 promoter. (D,E) PB-SPc-GFP and PB-Pgk-GFP are transposons that
accommodate the GFP sequence respectively under the SPc5–12 or the Pgk promoter. All the transposon constructs are flanked by wild-type inverted
repeats (IR) and loxP sites (loxP). All the transgenes in the transposon constructs are followed by the simian virus 40 late polyadenylation signal (pA). The
transposase constructs are instead represented from (F) to (H) (54).
exposing the cells upon reaching 80% of confluence to a
specific differentiation medium composed of DMEM sup-
plemented with 2% horse serum (Euroclone), 1% P/S, 1%
L-glutamine for 4 to 10 days (53). C2C12 cells were in-
duced to differentiate on a 6-well multidish (Nunc), while
GRMD MABs and SKM cells were seeded onto matrigel
(BDBiosciences) coated dishes.When cells were transduced
with the tamoxifen-inducible MyoD-ER lentiviral vector,
1 M 4-hydroxy-tamoxifen (Sigma-Aldrich) was added in
the growth medium that was replaced 24 h later by dif-
ferentiation medium supplemented with 1 M 4-hydroxy-
tamoxifen. Half of the medium was replaced with fresh
differentiation medium every other day. Immunofluores-
cence (IF) staining for myosin heavy chain (MyHC) was
performed to confirmmultinucleated myotubes (see specific
section for ‘IF staining’). Differentiation of GRMDMABs
in smooth muscle-like cells was induced by treating the cells
for 10 days with differentiation medium supplemented with
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5 ng/ml transforming growth factor 1 (Sigma-Aldrich)
(62). Smooth muscle differentiation was confirmed by IF
staining for -smooth muscle actin (SMA; see specific sec-
tion for ‘IF staining’).
Flow cytometry
Expression of CD44, CD34 and CD45 markers on GRMD
MABs was assessed after incubating the cells with specific
anti-dog fluorochrome-conjugated monoclonal antibodies
for 1 hour at 4◦C: anti-CD44-APC (FAB5449A; R&D
Systems), anti-CD34-PE (559369; BD Biosciences), anti-
CD45-RPE (MCA1042PE; AbD Serotec). Cells were sub-
sequently washed with PBS and fixed in 2% paraformalde-
hyde (Sigma-Aldrich). Cytofluorimetric analysis was per-
formed using a FACSCantoTM flow cytometer and FACS-
Diva software. At least 10,000 events were acquired for each
sample.
Immunofluorescence staining
In vitro differentiated C2C12 cells or GRMD MABs
were washed with PBS (Sigma-Aldrich), fixed with 4%
paraformaldehyde (Sigma-Aldrich) at room temperature
(RT) for 10 min and permeabilized with PBS containing
0.2% Triton X-100 (Sigma-Aldrich) and 1% BSA (Sigma-
Aldrich) at RT for 30 min. As a blocking solution, 10%
donkey serum (Sigma-Aldrich) was used at RT for 30
min to reduce secondary antibody background signal. The
cells were subsequently incubated overnight at 4◦C with
the following primary antibodies: rabbit anti-turboGFP
(AB513; Evrogen), mouse anti-dystrophin (NCL-DYS1,
NCL-DYS2, NCL-DYS3; Novocastra), mouse anti-myosin
heavy chain (MyHC MF20; Developmental Studies Hy-
bridoma Bank, USA), rabbit anti-myosin (476126; Cal-
biochem), mouse anti-myogenin (F5D; Developmental
Studies Hybridoma Bank, USA), rabbit anti-MyoD (M-
318; Santa Cruz), mouse anti-sarcomeric-actinin (ab9465;
Abcam),mouse anti- smoothmuscle actin (A2547; Sigma-
Aldrich). After incubation, cells were washed with PBS
and then incubated with the appropriate 488, 546, 594 or
647-fluorochrome conjugated secondary antibodies (Life
Technologies) together with Hoechst 33342 for nucleic
acid staining (B2261; Sigma-Aldrich) for 1 hour at RT in
PBS containing 0.2% Triton X-100. After three successive
washings with PBS, slides were mounted using fluorescent
mounting medium (Dako) and examined by fluorescence
microscopy (DMI6000B, Leica, Germany). Images were
analyzed using ImageJ software (NIH; http://rsbweb.nih.
gov/ij/download.html). The monoclonal antibody MF20
developed by Donald Fischman was obtained from the De-
velopmental Studies Hybridoma Bank (DSHB) developed
under the auspices of the National Institute of Child Health
andHumanDevelopment (NICHD) andmaintained by the
University of Iowa, Department of Biology, Iowa City, IA
52242.
Western blot
To assess the PB-mediated expression of the full-length
human dystrophin protein, C2C12 cells differentiated into
skeletal muscle in vitro were washed with cold PBS and
lysed in RIPA buffer in presence of CompleteMini protease
inhibitor mixture (Roche) for 30 min on ice. Cell lysates
were cleared and quantified. The following non-conjugated
primary antibodies were used: mouse anti-human dys-
trophin (NCL-DYS3; Novocastra) and mouse anti-myosin
heavy chain (MyHC MF20; Developmental Studies Hy-
bridoma Bank, USA). As secondary antibody, the HRP-
conjugated goat anti-mouse (Santa Cruz) was used. To de-
tect a housekeeping protein, theHRP-conjugated anti-beta-
tubulin (Abcam) was used. Signal was visualized by En-
hanced Chemiluminescent Reagents (ECL, Invitrogen) or
West Femto (Thermo Scientific), according to the manufac-
turer’s instructions. SKM cells differentiated into skeletal
muscle in vitro were used as positive control.
RNA analysis
Total RNA was extracted (RNeasy Mini Kit, QIAGEN)
and reversed transcribed using a cDNA synthesis kit
(SuperScript R© III First-Strand synthesis system for RT-
PCR kit, Life Technologies). For RT-PCR, cDNA was am-
plified on a PCR thermocycler (Biorad) with GoTaq DNA
Polymerase (Promega). Amplifications were performed us-
ing the primers listed in Supplementary data, Table S1, at
the annealing temperature of 60◦C for 25 cycles on C2C12
and 29 cycles on GRMD MABs. The amplified fragments
were resolved by electrophoresis on a 2% agarose gel. For
quantitative RT-PCR (qRT-PCR), cDNAwas amplified on
a Step-One Real-Time PCR System (Applied Biosystems;
Life technologies) with SYBR green PCRMaster mix (Ap-
plied Biosystem). In particular, the semi-quantitative RT-
PCRs for the characterization of GRMD MABs were per-
formed by using the primers listed in Supplementary data,
Table S2, at the annealing temperature of 60◦C for 33 cycles.
Amplicons were then resolved by electrophoresis on a 2%
agarose gel. Whilst the transgene mRNA levels in treated
and untreated C2C12 cells and GRMD MABs were deter-
mined by qRT-PCR, using the primers described in Sup-
plementary data, Table S3. Data were normalized to the
GAPDH housekeeping gene or to the MyHC gene specific
for the skeletal muscle differentiation. The expression levels
of the selected transgene was calculated using a standard
Ct method (63).
Transposon copy number
The number of copies of PB transposon integrated per cell
(diploid genome) was calculated by performing a qPCR on
genomic DNA (DNeasy Blood & Tissue Kit, Qiagen) by
using primers specific for the 5′ inverted repeat region (5′
IR) of the PB transposon, as previously described (54). The
standard curve was determined by a known copy number
of the corresponding PB transposon plasmid.
Statistical analysis
Data were presented as mean and standard deviation (SD)
or standard error of the mean (SEM). Comparison be-
tween groups was performed by using two-tailed unpaired
Student’s t-test or two-way ANOVA (Bonferroni’s multiple
comparison test).
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RESULTS
Generation ofPB transposons encoding for human dystrophin
CDS
We generated PB transposons designed to express the full-
length or truncated versions of a codon-optimized human
dystrophinCDS (59) from themuscle-specific synthetic pro-
moter SPc5–12 (346 bp) (57,58,64) (Figure 1). The simian
virus 40 (SV40) late polyadenylation signal (pA) was in-
corporated as transcription terminator in all the expression
cassettes. Given the large cargo that PB transposons could
accommodate (32,33), we generated a large-size transposon
named PB-SPc-DYS-Pgk-GFP encoding for the full-length
human dystrophin CDS (huDYSco; size: 11.1 kb) driven
by the synthetic SPc5–12 promoter, and a GFP reporter
transgene driven by the constitutive phophoglycerate ki-
nase 1 (Pgk) promoter (transposon size: 17 kb) (Figure 1A).
PB-SPc-MD1 (Figure 1B) and PB-SPc-MD2 (Figure 1C)
transposons encoded respectively for two different codon
usage-optimizedmicrodystrophinCDS: huMD1co (size: 3.6
kb) and huMD2co (size: 4 kb) whereby the C-terminal do-
main was deleted in huMD1co (58) (transposon size: 8.2 kb
and 8.6 kb, respectively). As controls, PB-SPc-GFP (Figure
1D) andPB-Pgk-GFP (Figure 1E) transposons carried only
the copepod GFP sequence under the control of the SPc5–
12 or the constitutive Pgk promoter (transposon size: 5.2
kb and 5.4 kb, respectively). The transposase plasmids in-
cluded the mPB expression plasmid, encoding the murine
codon-optimized, non-hyperactive PB transposase (Figure
1F) and the hyPB expression plasmid encoding the murine
codon-optimized, hyperactive PB transposase (Figure 1G).
An empty plasmid that contained an identical expression
cassette, but devoid of transposase (Figure 1H), was em-
ployed as control (54).
Expression of human microdystrophins after PB-mediated
transposition in C2C12 myoblasts
We first tested the functionality of the PB-SPc-GFP, PB-
SPc-MD1 and PB-SPc-MD2 transposons since they are
smaller in size and therefore easier to transfer into the
target cells. C2C12 cells, a murine myoblast cell line (52),
were co-transfected by electroporation with the PB-SPc-
GFP transposon and the mPB transposase-encoding con-
struct (ratio of 1.26 pmol transposase DNA: 3.48 pmol
transposon DNA). In parallel, PB-SPc-MD1 and PB-SPc-
MD2 transposons were electroporated under the same con-
ditions. To determine the transfection efficiency of mPB
transposase and PB-SPc-GFP transposon, FACS analy-
sis was performed 48 h post-electroporation (EP), showing
26±4% GFP+ cells which remained relatively stable (24 ±
4%GFP+ cells at 72 h post-EP; not statistically significant)
(Figure 2A, left panel). As control, the empty expression
plasmid- devoid of mPB transposase gene- was electropo-
rated with thePB-SPc-GFP transposon resulting initially in
comparable transfection efficiencies at 48 h (17± 1%GFP+
cells). However, in contrast to when the mPB expression
vector was employed, the percentage of GFP+ transfected
cells gradually declined at 72 h post-EP, consistent with the
loss of non-integrated PB-SPc-GFP plasmids in the rapidly
dividing C2C12 cells (9±1% GFP+ cells; p≤ 0.01). Simi-
larly, the mean fluorescent intensity (MFI) was sustained
when the PB-SPc-GFP transposon was co-transfected with
mPB and significantly different from the controls (p≤ 0.001)
(Figure 2A, right panel). These FACS data were confirmed
by live cell imaging (Figure 2B).
Subsequently, we assessed whether C2C12 cells trans-
posed with the PB transposons retained their ability to dif-
ferentiate into skeletal muscle andwhether expression of the
GFP and microdystrophins MD1 and MD2, encoded by
the transposons, was sustained upon differentiation. Four
days after incubation with the differentiation medium (cor-
responding to 10 days post-EP), multinucleated myotubes
were observed. The transcription levels of GFP (Figure 2C)
and the human microdystrophins MD1 and MD2 (Figure
2D) were detectable by qRT-PCR and showed a signifi-
cantly increased expression upon differentiation (P ≤ 0.01
for GFP, P ≤ 0.001 for the microdystrophins). This con-
firmed the muscle-specificity of the synthetic SPc5–12 pro-
moter, consistent with its up-regulation upon myogenic dif-
ferentiation. The transcript levels of the microdystrophins
MD1 andMD2 in the differentiated C2C12 cells were com-
parable to the level of human dystrophin transcripts in dif-
ferentiated human skeletal muscle (SKM) cells (Figure 2D).
In contrast, we were not able to detect any GFP expression
from differentiated C2C12 cells that were co-transfected
with the empty plasmid and the PB-SPc-GFP transposon
(Figure 2C). This indicates that transposition was a prereq-
uisite to ensure stable GFP transcript levels. Immunofluo-
rescence (IF) staining independently confirmed GFP (Fig-
ure 2E) and human microdystrophin MD1 and MD2 ex-
pression (Figure 2F) respectively in the myosin heavy chain
(MyHC) and myosin positive myotubes, derived from the
transposed C2C12 cells. The percentage of myotubes posi-
tive forGFP,MD1orMD2was determined by counting the
nuclei within these myotubes divided by the total number
of nuclei within the MyHC positive myotubes (68±6% for
GFP; 65±2% for MD1 and 66±2% for MD2, respectively).
Collectively, these results demonstrate that the PB trans-
poson system is well suited to achieve sustained muscle-
specific expression of human microdystrophins upon trans-
position in differentiated myogenic cells. The validation of
the PB transposon system for the delivery of the truncated
human dystrophins paves the way toward the use of the full-
length human dystrophin.
Increased transposition in C2C12 myoblasts with the hy-
peractive PB transposase and the PB transposon encoding
the full-length human dystrophin CDS
Different research groups, including ours, have shown
that the hyPB transposase resulted in increased transposi-
tion as compared to the mPB transposase (37,38,54,65). In
line with these results, we therefore assessed the transposi-
tion efficiency of hyPB transposase in a head-to-head com-
parison with themPB transposase, along with the large-size
transposon PB-SPc-DYS-Pgk-GFP (17 kb) in C2C12 my-
oblasts. This represents the first attempt in delivering the
full-length dystrophin CDS by the PB transposon system.
The mPB or hyPB-encoding expression constructs were
electroporated together with PB-SPc-DYS-Pgk-GFP trans-
poson in C2C12 myoblasts (ratio of 0.32 pmol transposase
DNA: 0.87 pmol transposon DNA). Controls were trans-
fected with the empty expression plasmid devoid of any
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Figure 2. PB-mediated expression of MD1 and MD2 in C2C12 myoblasts. (A) The bar graphs show respectively the percentage of GFP+ (left) and the
mean fluorescence intensity (MFI; right) of C2C12 cells at 48 and 72 h post-electroporation (EP) with the PB-SPc-GFP transposon when co-transfected
with the native mPB transposase or the empty plasmid (ratio of 1.26 pmol transposase DNA: 3.48 pmol transposon DNA). Untransfected cells are also
shown. Shown aremean±SEMof three independent biological replicates; two-tailed unpaired Student’s t-test (***P≤ 0.001; **P≤ 0.01; *P≤ 0.05; ns: not
significant). (B) Live cell imaging showing the GFP expression of the conditions described in (A) at 24, 48 and 72 h post-EP (UNTR: untransfected; scale
bar 100m). (C,D) The bar graphs depict the transcript levels of GFP (C) orMD1 andMD2 (D) detected by qRT-PCR inPB-transposed C2C12myoblasts
in proliferation (white bars) and myotubes in differentiation (black bars). The transcript levels of the human dystrophin from the human skeletal muscle
(SKM) cells and myotubes were used as positive control. Values were normalized for the myosin heavy chain (MyHC) and shown as relative expression.
Shown are mean±SEM of triplicate qRT-PCR analyses performed for three independent biological replicates; two-tailed unpaired Student’s t-test (***P≤
0.001; **P≤ 0.01; ns: not significant). (E,F) Immunofluorescence staining on transposed C2C12 cells upon skeletal muscle differentiation in vitro has been
used to detect the GFP expression (E, in green) in MyHC positive myotubes (E, in red), or the human microdystrophins MD1 and MD2 expression (F, in
green) in myosin positive myotubes (F in red). The nuclei were stained with Hoechst (Scale bar 100 m). The mouse anti-human dystrophin NCL-DYS3
antibody was used.
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Figure 3. Validation of the use of hyPB transposase in C2C12 myoblasts.
(A) Live cell imaging depicting the GFP expression in C2C12 myoblasts at
different time points after sorting, when the large-size transposonPB-SPc-
DYS-Pgk-GFP is co-transfected with hyPB ormPB transposase (Scale bar
100m). (B) Graphs representing the comparison between hyPB andmPB
transposases in terms of percentage of GFP+ population (graph above)
and mean fluorescence intensity (MFI, graph below). The GFP+ popula-
tions were enriched by FACS at 4 days post-EP andmonitored for theGFP
expression in the next 30 days after the sorting. The higher efficiency of
the hyPB transposase over the mPB transposase was assessed at the con-
centration of 0.32 pmol transposase DNA: 0.87 pmol transposon DNA.
Results were presented as mean±SD of three independent biological repli-
cates; two-way ANOVA (Bonferroni’s multiple comparison test); ***P ≤
0.001; **P ≤ 0.01.
PB transposase and with the PB-SPc-DYS-Pgk-GFP trans-
poson. Due to the large size transposon, the percentage
of GFP positive C2C12 myoblasts at 4 days post-EP re-
sulted to be 4±0.5% after co-transfection with the hyPB
transposase and 2±0.5% after co-transfectionwith themPB
transposase. The GFP positive populations were then en-
riched by FACS sorting and monitored at different time
points by FACS analysis and fluorescence microscopy (Fig-
ure 3A, B). At 30 days post sorting, 78 ± 3% of the cells
transfected with the hyPB transposase were GFP positive,
showing a statistically significant (P≤ 0.01) higher percent-
age compared to when the mPB was employed (63 ± 3%
GFP positive cells). Consistently, a statistically significant
difference in MFI (P ≤ 0.001) was detected by FACS when
the hyPB was used compared to the mPB (Figure 3B).
We subsequently assessed whether C2C12 cells trans-
posed with the hyPB transposase and the large-size trans-
poson PB-SPc-DYS-Pgk-GFP expressed the human full-
length dystrophin and retained their ability to differenti-
ate into skeletal muscle. Four days after incubation with
the differentiation medium (corresponding to 24 days post-
EP), multinucleated myotubes were observed. The tran-
scription levels of the full-length human dystrophin were
detectable by qRT-PCRand showed a significant increase in
expression in C2C12 cells differentiated in myotubes com-
pared to when the cells were retained in a proliferative, non-
differentiated state (P ≤ 0.001; Figure 4A). This is con-
sistent with our previous results (Figure 2C, D) and con-
firms the muscle-specificity of the synthetic SPc5–12 pro-
moter and its up-regulation upon myogenic differentiation.
To demonstrate that the full-length human dystrophinCDS
expresses a full-length transcript, a reverse transcriptase
(RT)-PCR was first performed using three different primer
pairs that respectively amplify three different regions of the
full-length dystrophin transcript, including the N-terminal,
central and C-terminal sequences (Supplementary data, Ta-
ble S1). The three bands corresponding to these respective
amplified regions were detected in differentiatedC2C12my-
oblasts that had undergone transposition after transfection
with the hyPB transposase and the PB-SPc-DYS-Pgk-GFP
transposon constructs (Figure 4B). In contrast, these spe-
cific PCR bands were absent in the untreated differentiated
C2C12 cells or in differentiated C2C12 cells co-transfected
with the PB-SPc-DYS-Pgk-GFP transposon and an empty
expression plasmid without transposase (Figure 4B).
Western blot analysis subsequently confirmed expression
of the full-length human dystrophin protein (427 kDa)
in myotubes derived from C2C12 cells that had under-
gone transposition after transfection with the hyPB trans-
posase and the PB-SPc-DYS-Pgk-GFP transposon con-
structs (Figure 4C). Dystrophin expression in these my-
otubes coincided with GFP and myosin expression, as con-
firmed by immunofluorescence (Figure 4D and E). Simi-
larly, Western blot analysis demonstrated expression of the
full-length human dystrophin protein (427 kDa) in differ-
entiated normal human skeletal muscle cells (SKM, Fig-
ure 4C), whereas no dystrophin expression was apparent in
non-transfected differentiated C2C12 cells or differentiated
C2C12 cells co-transfectedwith thePB-SPc-DYS-Pgk-GFP
transposon and an empty expression plasmidwithout trans-
posase (Figure 4C).
Collectively, these results justify the use of hyperactivePB
transposase to achieve a stable integration of the PB trans-
poson encoding for the full-length human dystrophin and
a sustained expression of the protein in differentiated myo-
genic cells.
Isolation and characterization of adult skeletal muscle
pericyte-derived stem/progenitor cells from the Golden Re-
triever Muscular Dystrophy (GRMD) dog model
Adult pericyte-derived stem/progenitor cells orMABswere
isolated from the skeletal muscle of a Golden Retriever
MuscularDystrophy (GRMD) dog, as previously described
(45,53). Small, round, refractile and poorly adherent cells
were visible with the initial outgrowth of adherent cells
(Supplementary Figure S1A). This population of cells was
collected, kept in culture and characterized for the typi-
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Figure 4. Human full-length dystrophin expression in PB-transposed C2C12 myoblast-derived differentiated myotubes. (A) The transcript levels of the
full-length human dystrophin (black bars) and the GFP (white bars) were detected by qRT-PCR in C2C12 cells transposed with hyPB + PB-SPc-DYS-
Pgk-GFP, while in proliferation or in differentiated myotubes (D: differentiated sample). Results were presented as mean±SEM of triplicate qRT-PCR
analyses performed for three independent biological replicates; two-tailed unpaired Student’s t-test (***P≤ 0.001; ns: not significant). (B) RT-PCR showing
expression of full-length human dystrophin transcript in myotubes derived from C2C12 cells that had undergone transposition after co-transfection with
hyPB and PB-SPc-DYS-Pgk-GFP. Three different primer pairs were used that recognize respectively (1) the N-terminal, (2) a central region and (3) the
C-terminal sequences, yielding amplicons of 221 bp, 222 bp and 228 bp, respectively. A schematic representation of the PCR primers relative to the different
regions of the dystrophin transcript is depicted. Human skeletal muscle cells (SKM) differentiated in myotubes were used as a positive control. Negative
controls included untreated differentiated C2C12 cells (designated as C2C12) or differentiated C2C12 cells co-transfected with the PB-SPc-DYS-Pgk-
GFP transposon and an empty expression plasmid without transposase (designated as Empty). L: 50 bp ladder. (C) Western blot analysis demonstrating
expression of the full-length human dystrophin protein (427 kDa) in myotubes derived from C2C12 cells that had undergone transposition after co-
transfection with hyPB and PB-SPc-DYS-Pgk-GFP. The antibody NCL-DYS3 was used to detect the human dystrophin. Non-transfected differentiated
C2C12 cells or differentiated C2C12 cells co-transfected with thePB-SPc-DYS-Pgk-GFP transposon and an empty expression plasmidwithout transposase
were included as negative controls. Normal human skeletal muscle cells were used as positive control. In vitro skeletal muscle differentiation was confirmed
for all the samples by the expression of the MyHC protein (223 kDa). -Tubulin (50 kDa) was used to normalize the amount of loaded proteins. (D, E)
Immunofluorescence staining on C2C12 myotubes upon 4 days in conditioning medium (24 days post-EP) C2C12 cells transposed with hyPB + PB-SPc-
DYS-Pgk-GFP showed a co-localized expression of GFP (D, in green) and full-length human dystrophin (D, E in red) when differentiated in myotubes,
as confirmed by the myosin expression (E, in white). The nuclei were stained with Hoechst (Scale bar 100 m). The Ab mouse anti-human dystrophin
NCL-DYS3 was used.
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cal markers of adult skeletal muscle MABs (43,53). Alka-
line phosphatase (AP) positive cells were detected in the
cultured cell population (Supplementary Figure S1B). The
presence of the CD44 marker and the absence of CD34 and
CD45 markers were assessed by FACS analyses, showing
the typical profile of this subset of adult pericytes (Supple-
mentary Figure S1C). Further markers were subsequently
analyzed by semi-quantitative RT-PCR at different time
points (passage P5 and P10), using as a positive control a
heterogeneous bulk cell population directly derived from
the GRMD muscle biopsy (passage P1). As expected, the
transcript levels of PAX7, MYF5, CD56 and desmin, typ-
ically associated with satellite cells, decreased significantly
after the first passage (P ≤ 0.01, P ≤ 0.001; Supplemen-
tary Figure S1D, SE). In contrast, the transcript levels of
NG2 and PDGFRβ, typical markers of pericytes, remained
stable over time. Finally, the isolated cell population was
capable to spontaneously differentiate in vitro into skeletal
myotubes or into mesodermal lineages upon appropriated
stimulation (Supplementary Figure S1F, SG). Collectively,
this gene expression profile and functional analyses con-
firmed that the GRMD cell isolated were bona fideMABs.
Genetic correction of dystrophic mesoangioblasts by delivery
of the full-length human dystrophin CDS in PB transposon
system
We subsequently optimized the transfection conditions of
the dystrophic GRMD MABs. These were transfected by
electroporation with the hyPB transposase-encoding con-
struct and the PB-Pgk-GFP transposon (ratio of 0.32 pmol
transposase DNA: 0.87 pmol transposon DNA) showing
a transfection efficiency of 44 ± 1% GFP+ cells at 7 days
post-EP (Figure 5A). The transfected cells were sorted and
the GFP expression was maintained, resulting in 88 ± 3%
GFP+ cells at 28 days post sorting (P ≤ 0.001; Figure 5B).
In contrast, in the absence of the hyPB transposase, the
percentage of GFP+ cells gradually declined resulting in
only background levels of GFP, indistinguishable from un-
transfected control GRMD MABs (Figure 5B). This indi-
cates that the sustained GFP expression in the transfected
MABs could be ascribed to and is dependent on bona fide
transposition. Based on these encouraging results, we sub-
sequently transfected theGRMDMABs by electroporation
with the same molar ratios of hyPB transposase expression
construct and the large-size transposon PB-SPc-DYS-Pgk-
GFP (ratio of 0.32 pmol transposaseDNA: 0.87 pmol trans-
poson DNA), encoding both full-length human dystrophin
and GFP. This resulted in a transfection efficiency of 3 ±
1% GFP+ cells at 7 days post-EP (Figure 5A). The differ-
ence in transfection efficiency between the equimolar doses
of PB-SPc-DYS-Pgk-GFP and PB-Pgk-GFP transposons
reflected the different sizes of the plasmids, as previously
reported (P ≤ 0.001, Figure 5A) (66). Though doubling
the hyPB transposase and transposon doses, while main-
taining the transposase: transposon ratio, further increased
the percentage of GFP+ cells (Supplementary Figure S2),
the viability of the transfected cells concomitantly declined
(P ≤ 0.001). GRMD MABs transfected with hyPB trans-
posase and PB-SPc-DYS-Pgk-GFP transposon were sorted
at 7 days post-EP, and the GFP expression was monitored
by FACS analysis and fluorescence microscopy during the
28 days post sorting (Figure 5B, C). The transfected cells
exhibited stable expression of 50 ± 5% GFP+ cells, con-
sistent with stable transposition (P ≤ 0.001). The transpo-
son copies per diploid genome quantified by qPCR corre-
sponded to 0.5 ± 0.03 copies for the condition hyPB + PB-
SPc-DYS-Pgk-GFP and 1.7 ± 0.04 copies for hyPB + PB-
PgkGFP (Figure 5D). GRMDMABs that were transfected
with the transposon and without the transposase did not
show any detectable integrated transposons (P≤ 0.001), in-
distinguishable from non-transfected control cells.
To assess if the integrated PB-SPc-DYS-Pgk-GFP trans-
poson could result in sustained expression of the full-length
human dystrophin, transposed GRMDMABs were subse-
quently differentiated in vitro into myocytes/myotubes af-
ter tamoxifen-induced overexpression of MyoD-ER (61).
This approach allowed to rescuemyogenic differentiation of
adult canine MABs at late passages (i.e. passage P15–18).
The transcript levels of the full-length human dystrophin
were detected by qRT-PCR (P ≤ 0.001; Figure 6A). More-
over, the three different regions including the N-terminal,
the central region and the C-terminal region of the full-
length human dystrophin transcript were detected by RT-
PCR in the differentiated GRMD MABs that had under-
gone transposition after transfection with the hyPB trans-
posase and the PB-SPc-DYS-Pgk-GFP transposon con-
structs (Figure 6B). The expression of the full-length human
dystrophin protein was confirmed by immunofluorescence
in differentiated GRMD MABs, where it co-localized with
the expression of GFP (Figure 6C) and myosin (Figure 6D)
in genetically corrected myocytes/myotubes. In contrast,
dystrophin and GFP were not detectable in untransfected
cells nor in the control GRMD MABs co-transfected with
the PB-SPc-DYS-Pgk-GFP transposon and the empty ex-
pression plasmid without transposase (Figure 6C, D). This
was consistent with the lack of dystrophin mRNA in these
controls (Figure 6A, B). Similarly, sustained GFP tran-
script levels were detected by qRT-PCR in GRMD MABs
that had undergone transposition after co-transfection with
hyPB transposase andPB-Pgk-GFP transposon (P≤ 0.001;
Figure 6A). The GFP expression was confirmed by IF in
differentiated cells (Supplementary Figure S3). In the ab-
sence of the hyPB transposase, GFP transcript and protein
were absent, confirming the need for transposition to en-
able stable integration and transgene expression (Figure 6A,
Supplementary Figure S3).
Taken together, these findings demonstrate that it is
possible to genetically correct dystrophic adult mesoan-
gioblasts by using a PB-transposon based platform to de-
liver the full-length human dystrophin CDS.
DISCUSSION
In this study, we demonstrated that the PB transposon
platform could be used to obtain stable expression of
a therapeutically relevant, large-sized transgene such as
the human full-length dystrophin coding DNA sequence
(CDS), leading to the correction of dystrophic myogenic
stem/progenitor cells derived from a dystrophic large an-
imal model. Recent studies have tried to explore the use
of transposons to investigate therapeutic strategies in mus-
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Figure 5. PB-mediated transposition of the full-length human dystrophin CDS in GRMD MABs. (A) The bar graph shows the percentage of GFP+
GRMD MABs at the day of the sorting performed at 7 days post-EP. Optimized and equimolar doses have been used in the different conditions. The
statistically significant difference in transfection efficiency detected when PB-SPc-DYS-Pgk-GFP or PB-Pgk-GFP transposon are deployed reflects the
different sizes of the plasmids. Results were presented as mean±SEM of three independent biological replicates; two-tailed unpaired Student’s t-test (***P
≤ 0.001; ns: not significant). (B) The GFP+ populations were monitored at different time points for 28 days post sorting. GRMD MABs co-transfected
with the empty plasmid and the same transposons, and untransfected cells were used as controls. Shown are mean±SD on a biological replicate; two-way
ANOVA (Bonferroni’s multiple comparison test); ***P ≤ 0.001. (C) Live cell imaging showing the GFP expression of the different conditions at day 21
post sorting (Scale bar 100 m). (D) Bar graph representing the transposon copies per diploid genome detected by qPCR in transposed GRMD MABs
(PB-SPc-DYS-Pgk-GFP 0.5 ± 0.03 copies/cell; PB-Pgk-GFP 1.7 ± 0.04 copies/cell). Shown are mean±SEM of triplicate qRT-PCR analyses performed
for a biological replicate; two-tailed unpaired Student’s t-test (*** P ≤ 0.001; **P ≤ 0.01).
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Figure 6. Correction of GRMD MABs by the PB-mediated expression of the full-length human dystrophin. (A) The transcript levels of the full-length
human dystrophin (black bars) and GFP (white bars) were detected by qRT-PCR analysis in GRMDMABs transposed with hyPB + PB-SPc-DYS-Pgk-
GFP or PB-Pgk-GFP. SKM cells have been used as positive control. Samples are indicated with (D) when differentiated in myocytes/myotubes. Results
were presented as mean±SEM of triplicate qRT-PCR analyses performed for a biological replicate; two-tailed unpaired Student’s t-test (***P≤ 0.001; **P
≤ 0.01; ns: not significant; D: differentiated sample). (B) RT-PCR demonstrating expression of full-length human dystrophin transcript in differentiated
GRMD MABs that had undergone transposition after co-transfection with hyPB and PB-SPc-DYS-Pgk-GFP. Three different primer pairs were used
that recognize respectively (1) the N-terminal, (2) a central region and (3) the C-terminal sequences, yielding amplicons of 221 bp, 222 bp and 228 bp,
respectively. A schematic representation of the PCR primers relative to the different regions of the dystrophin transcript is depicted. Controls included
differentiated human SKM, untreated differentiated MABs (designated as GRMDMABs) and differentiated GRMDMABs co-transfected with the PB-
SPc-DYS-Pgk-GFP transposon and an empty expression plasmid without transposase (designated as Empty). L: 50 bp ladder. (C,D) At 21 days post-EP,
GRMDMABs corrected with hyPB + PB-SPc-DYS-Pgk-GFPwere induced to differentiate in skeletal muscle in vitro uponMyoD-ER overexpression and
6 days in conditioning medium. Immunofluorescence analysis confirms the expression and co-localization of the full-length human dystrophin (C, D in
red) with the GFP (C, in green), or with the myosin (D, in white). The conditions empty plasmid + PB-SPc-DYS-Pgk-GFP as well as the untransfected cells
are also shown as negative controls. The nuclei were stained with Hoechst (Scale bar 100 m). The mouse anti-dystrophin NCL-DYS1 and NCL-DYS2
antibodies were used.
cular dystrophies, but they were limited to the use of re-
porter or marker genes (67–69), truncated versions of either
dystrophin or utrophin (70,71) or conditionally immortal-
izedmuscle cell-derived cell-lines (67,70), that cannot be de-
ployed clinically. To our knowledge, this is the first report
that establishes the use of PB transposons encoding for the
full-length human dystrophin enabling genetic correction of
dystrophic primary cells. This represents a proof of concept
study toward the development of a novel stem cell-based
gene therapy approach for Duchenne muscular dystrophy
with potentially broad implications for the field at large.
The main advantage of PB transposons is that they effi-
ciently integrate their cargo into the target cell genome. This
property enables robust stable gene expression in both hu-
man and mouse cells, ex vivo or in vivo (33,37–39,54,60,72).
This attribute is particularly relevant for stable genetic
modification of stem/progenitor cells, given their intrinsic
self-renewal and differentiation potential (73). As we ob-
served in this study, PB transposons can integrate and pro-
vide dystrophin expression in dystrophic mesoangioblasts
(MABs) and their differentiated progeny. In contrast, only
transient or no expression was observed in the absence
of any transposase-encoding construct. This indicates that
bona fide transposition was a prerequisite for a robust dys-
trophin expression in dystrophic MABs. It is known, in-
deed, that transfection of conventional plasmids results in
a very low stable integration frequency (typically 1 stable
integrant per 105 transfected cells) (60) that consequently
hampers potential clinical applications. The efficiency of
PB transposon-mediated delivery of the full-length human
dystrophin CDS compares favorably with alternative ap-
proaches that allowed the production of the wild-type full
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length dystrophin protein, such as the human artificial chro-
mosome (HAC; (74,75)). This vector is recognized as an
endogenous chromosome within the host cells and is sta-
bly maintained throughout subsequent cell divisions obvi-
ating the need for genomic integration. The entire human
dystrophin genomic locus (2.4 Mb), including the native
promoter and regulatory elements, has been accommodated
into the HAC (76,77) and transferred in dystrophic murine
mesoangioblasts and DMD patient specific human iPSC-
derived mesoangioblast-like cells (47,78). This approach re-
sulted in the full-length human dystrophin expression in
genetically corrected cells. Nevertheless, the generation of
such a relatively complex vector like theHAC, together with
the low efficiency of microcell-mediated chromosome trans-
fer (MMCT; approximately 1.2 x 10−5) required to intro-
duce HACs into the target cells, may limit the application
of this technology only to clonogenic stem/progenitor cells
with high proliferation potential. On the other hand, the use
of PB transposons is at least 104-fold more efficient than
MMCT and may ease the manufacturing constrains com-
pared to MMCT or viral vectors, ultimately facilitating ul-
timate clinical translation of the PB transposon vectors.
Another advantage of thePB transposons is that they en-
abled stable delivery of the full-length human dystrophin
CDS together with a reporter marker (insert size: 13.7 kb).
This exceeds the packaging capacity of  -retroviral and
lentiviral vectors (<10 kb) and AAV vectors (5 kb). Con-
sequently, this obviates concerns associated with the use of
truncated dystrophins that may not replicate all of the nec-
essary functions of its wild-type counterpart (45). More-
over, expression of full-length human dystrophin is broadly
applicable to all patients suffering from DMD, regardless
of the underlying genetic defect in the dystrophin locus.
This is in contrast with other approaches that are restricted
in their application to correcting specific mutations of the
gene, such as exon-skipping strategies (18,79,80) or the use
of engineered nucleases (81–83). The ability of PB trans-
posons to deliver such a relatively large cargo is consis-
tent with previous reports indicating that PB transposons
can mediate the transfer of large genetic cargos up to 100
kb (32,33). The availability of PB transposons encoding ei-
ther full-length or truncated dystrophin CDS characterized
in this study may pave the way toward future comprehen-
sive structure-function and comparative studies. Indeed, the
present study has broader implications for the use of other
hyperactive transposon systems, such as Sleeping Beauty for
gene therapy of DMD (84–86).
In the present study, we have used nucleofection tech-
nology, an electroporation-based transfection method that
allows to transfer the DNA plasmids directly into the nu-
clei and the cytoplasm of both dividing and non-dividing
the cells in vitro. This technique overcomes the limitations
related to other transfection methods that rely on nuclear
import of plasmid DNA in non-dividing cells (i.e. poly-
cations). However, large-size DNA plasmids adversely im-
pact on the transfection efficiency (66). In accordance with
these previous findings, we showed that the use of large
transgenes (e.g. full-length human dystrophin CDS as op-
posed to truncatedMD1andMD2humanmicrodystrophin
CDS) and/or increasing DNA concentrations resulted in a
net decrease in transfection efficiency. This may be due, at
least in part, by the intrinsic property of the DNA plasmids
such as the presence of unmethylated CpG motifs in the
backbone sequences that might impair cell viability, pos-
sibly involving Toll-like receptor (TLR) pathways (87,88).
Indeed, plasmids with a low content in CpG motifs con-
fer long-term gene expression with less toxicity (89,90). Al-
ternatively, transfection efficiency may also have been af-
fected by nuclear import of plasmid DNA in non-dividing
cells and/or reduced cytosolic mobility of large size plas-
mid DNA (91). Nevertheless, the surviving transfected cells
could be easily enriched by FACS sorting yielding more
than 50% MABs that had undergone stable transposition.
Moreover, we demonstrated that the use of the hyperac-
tive PB transposase (37) compared to the native PB trans-
posase (92) can boost the efficiency and stable expression of
large-size transposons, allowing the use of lower amounts
of DNA plasmids, and consequently reducing overall DNA
toxicity in the transfected cells. Nevertheless, it may be
worthwhile to further explore alternative strategies to aug-
ment the overall transfection efficiency, viability and ex-
pression of the therapeutic gene. This could potentially be
achieved by using aminicircle-based transposon system, de-
void of any bacterial backbone sequence, as recently val-
idated for Sleeping Beauty (66). Consequently, this would
reduce the plasmid size, lower CpG content, increase trans-
fection efficiency and decrease DNA toxicity. Alternatively,
more potent muscle-specific promoters could be used to
drive expression of the full-length dystrophin CDS.
Though the genomic integration of the PB transposons
is required for sustained expression in dividing and dif-
ferentiating stem/progenitor cells, it could raise some
concerns related to the risk of insertional oncogenesis by
potentially activating oncogenes that are in the vicinity
of the integration sites (93). PB transposons exhibit a
random integration pattern in the genome of murine
mesoangioblasts suggesting that they do not preferentially
integrate into genes and their regulatory regions (69). This
risk of insertional oncogenesis could be minimized further
by retargeting PB-mediated integration into potential
‘safe harbor’ loci (94,95). However, it is reassuring that
the PB transposon copy number detected in the present
study fell within an acceptable and relatively safe range of
genomic integrations per cell (i.e. 0.5–1.7 copies per diploid
genome), in accordance with the European medicines
agency guidelines (http://www.ema.europa.eu/ema/index.
jsp?curl=pages/regulation/general/general content 000410.
jsp&mid=WC0b01ac058002958d).
The therapeutic relevance ofMABs, even after prolonged
in vitro culture, has been highlighted in many previous stud-
ies (44–48). Their intrinsic capability to cross the wall ves-
sels when injected intra-arterially and to contribute to the
muscle regeneration in animal models has represented a
substantial advantage over other muscle stem cells (i.e. my-
oblasts) (42). We have confirmed the characteristic pheno-
type of theMABs used in our current study based on the ex-
pression of MAB markers (Supplementary Figure S1) and
their ability to undergo myogenic differentiation in vitro
(Supplementary Figures S1 and S3, Figure 6). According to
previous and recent studies on humanMABs, a high prolif-
eration rate has been observed for approximately 20 pop-
ulation doublings, with a doubling time of approximately
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36 h (42,49) without compromising their stem cell prop-
erties. Though the initial transfection efficiency in MABs
was about 3%, we could rapidly enrich for those cells that
had undergone stable transposition by FACS sorting, thus
avoiding protracted cell culture.
Dystrophin levels corresponding to 30% of the levels nor-
mally found in healthy individuals and in animal models are
sufficient to prevent muscular dystrophy (96,97). In accor-
dance with these data, pre-clinical studies based on the use
ofMABs have shown a therapeutic effect in dystrophicmice
and dogs with dystrophin expression ranging 20 to 30% of
normal levels (45,47). This has typically been achieved by
injecting 5 × 107 cells/kg in the dog model. Considering
treatment of pediatric subjects with less advanced muscle
disease and more likely to benefit from this cell therapy, this
would translate into a total cell dose of 75× 107 MABs in a
15 kg patient although the possibility of repeated injection
to reach efficacy still needs to be investigated. Up to 2 ×
109 human MABs can readily be obtained after in vitro ex-
pansion of initial cells isolated from a single muscle biopsy
(100–200 mg) (42,49). Based on our current results, we esti-
mated that 9× 108 stably transfectedMABs expressing dys-
trophin after PB-mediated transposition could be obtained
35 days post-transfection of 3 × 106 cells. Consequently,
the required dose to treat pediatric DMD patients is within
reach. It is encouraging that initially more MABs outgrew
from explants of young DMD patients (42) suggesting that
the yield of MABs and/or their proliferative capacity may
possibly be even higher in younger than in older patients
with advanced disease.
Allogeneic MABs have recently been tested in a first-
in-human phase I/II clinical trial in DMD patients under
immunosuppressive treatment (EudraCTN◦ 2011–000176–
33, (49)). Administration at escalating doses of HLA-
matched donor MABs in the limb arteries of the patients
was considered relatively safe, which was the primary end-
point of the study. One patient developed an acute thala-
mic stroke with no clinical consequences but it was unclear
whether it correlated with the MAB infusion. Muscle biop-
sies confirmed the presence of donor DNA in 4/5 patients
and expression of donor dystrophin in one patient. Though
no functional improvements were observed in the treated
patients, functional measures appeared to be stabilized in
2/3 ambulant patients. The study also provided insights
to further improve efficacy by enrolling younger patients
with less advancedmuscle disease and/or increase theMAB
dose.Moreover, the use of gene-modified autologousMABs
may further augment the efficacy with the added advantage
over allogeneicMABs that immune suppression may not be
needed in this case.
Though MABs can be expanded extensively for 20 pas-
sages and exhibit a remarkable proliferative potential, their
lifespan is limited nonetheless (53). This likely reflected nor-
mal cellular processes that gradually contribute to cellular
senescence (98). Nevertheless, this did not preclude clinical
translation (49). In addition, the PB transposon technology
is potentially amenable to be used in alternative adult myo-
genic stem cell sources distinct from MABs (99,100). Ul-
timately, the use of iPSC-derived myogenic cells, that have
unlimited expansion potential, may represent an attractive
alternative, provided they can safely and efficiently be con-
verted into transplantable myogenic cells (71,78,101–103).
In a separate study (Loperfido et al., unpublished observa-
tions), we genetically correctedDMDpatient-specific iPSC-
derived myogenic cells with the same PB transposon encod-
ing for the full-length human dystrophin and transplanted
the engineered cells in SCID/mdxmice. Dystrophin expres-
sion could be detected in vitro and in vivo by immunofluo-
rescence on the fibermembrane of the transplantedmuscles.
In conclusion, this study provides the first evidence of
PB-mediated human full-length dystrophin expression in
dystrophic MABs for the treatment DMD. Further char-
acterizations in vivo are needed upon transplantation of the
PB transposon-modified MABs in the GRMD model, to
ultimately justify a clinical study in patients suffering from
DMD.
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Supplementary Data are available at NAR Online.
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